Eyestem Gets CDSCO Approval for Phase 2 Blindness Treatment Trials
Eyestem Research has received CDSCO approval for Phase 2 clinical trials of Eyecyte-RPE, a stem cell therapy for geographic atrophy, a leading cause of blindness. This marks a significant advancement in India's regenerative medicine landscape.